• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Surmodics Inc. (Amendment)

    1/29/24 4:29:09 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care
    Get the next $SRDX alert in real time by email
    SC 13G/A 1 SRDX_SC13GA1.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    (AMENDMENT NO. 1)

    SURMODICS, INC.
    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.05 PER SHARE
    (Title of Class of Securities)

    868873100
    (CUSIP Number)

    DECEMBER 31, 2023
    (Date of event which requires filing of this statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         o Rule 13d-1(b)

         þ Rule 13d-1(c)

         o Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).



                         
    CUSIP No.
     
    868873100

    SCHEDULE 13G

    Page  
    2
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     671,551
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     671,551
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     671,551
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     4.7%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    868873100

    SCHEDULE 13G

    Page  
    3
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Group Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     671,551
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     671,551
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     671,551
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     4.7%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    868873100

    SCHEDULE 13G

    Page  
    4
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Israel A. Englander
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     671,551
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     671,551
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     671,551
    10
     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     4.7%
    12
     TYPE OF REPORTING PERSON

     IN

                         
    CUSIP No.
     
    868873100

     SCHEDULE 13G

    Page  
    5
      of   
    10
     
    Item 1.    
     
    (a) Name of Issuer:
     
       
     
      Surmodics, Inc.
     
       
     
    (b) Address of Issuer’s Principal Executive Offices:
     
       
     
     

    9924 West 74th Street
    Eden Prairie, Minnesota 55344

         
    Item 2.
    (a) Name of Person Filing:
     
    (b) Address of Principal Business Office:
     
    (c) Citizenship:
         
     
      Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Group Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Israel A. Englander
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: United States
     
       
      (d) Title of Class of Securities:
    common stock, par value $0.05 per share ("Common Stock")
     
      (e) CUSIP Number:
    868873100
     
     

    Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
      (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
                 
     
      (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
                 
     
      (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
                 
     
      (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
                 
     
      (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
     
      (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                         
    CUSIP No.
     
    868873100

     SCHEDULE 13G

    Page  
    6
      of   
    10
                 
     
      (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
                 
     
      (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
                 
     
      (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
                 
     
      (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount Beneficially Owned:

       See response to Item 9 on each cover page.

    (b) Percent of Class:   

       See response to Item 11 on each cover page.

     (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote

       See response to Item 5 on each cover page.


                         
    CUSIP No.
     
    868873100

     SCHEDULE 13G

    Page  
    7
      of   
    10

    (ii) Shared power to vote or to direct the vote

       See response to Item 6 on each cover page.

    (iii) Sole power to dispose or to direct the disposition of

       See response to Item 7 on each cover page.

    (iv) Shared power to dispose or to direct the disposition of

       See response to Item 8 on each cover page.

       The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5. Ownership of Five Percent or Less of a Class

       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

        Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

        Not applicable.

    Item 8. Identification and Classification of Members of the Group

        See Exhibit I.

    Item 9. Notice of Dissolution of Group

        Not applicable.

    Item 10. Certification 

       By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                         
    CUSIP No.
     
    868873100

    SCHEDULE 13G

    Page  
    8
      of   
    10

    Exhibits:

    Exhibit I:  Joint Filing Agreement, dated as of January 26, 2024, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                         
    CUSIP No.
     
    868873100

    SCHEDULE 13G

    Page  
    9
      of   
    10
                         
         

    SIGNATURE

                 

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: January 26, 2024

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander



                         
    CUSIP No.
     
    868873100

    SCHEDULE 13G

    Page  
    10
      of   
    10
                         
          EXHIBIT I              
                         
          JOINT FILING AGREEMENT              

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.05 per share, of Surmodics, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Dated: January 26, 2024

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander


    Get the next $SRDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRDX

    DatePrice TargetRatingAnalyst
    11/14/2025Mkt Perform → Underperform
    Barrington Research
    3/7/2025$43.00Hold → Buy
    Lake Street
    6/13/2023$36.00Hold → Buy
    Needham
    2/13/2023Buy → Hold
    Needham
    2/4/2022$70.00 → $58.00Buy
    Needham
    11/10/2021$76.00 → $70.00Buy
    Needham
    9/8/2021$68.00 → $76.00Buy
    Needham
    More analyst ratings

    $SRDX
    SEC Filings

    View All

    SEC Form 15-12G filed by Surmodics Inc.

    15-12G - SURMODICS INC (0000924717) (Filer)

    12/1/25 4:32:00 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Surmodics Inc.

    EFFECT - SURMODICS INC (0000924717) (Filer)

    11/21/25 12:15:02 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Surmodics Inc.

    SCHEDULE 13D/A - SURMODICS INC (0000924717) (Subject)

    11/20/25 4:06:14 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today

    Surmodics, Inc. (NASDAQ:SRDX) ("Surmodics" or the "Company"), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that it expects to close its previously announced acquisition (the "Merger") of the Company by an affiliate of GTCR LLC ("GTCR") promptly. In a joint status report filed with the United States District Court for the Northern District of Illinois (the "District Court"), the Federal Trade Commission ("FTC") and certain state regulators ("Plaintiffs") stated that they do not intend to appeal the November 10, 2025 ruling by the District Court denying the Plaintiffs' motion for a preliminary injunction to prevent the

    11/17/25 6:00:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR

    Surmodics, Inc. (NASDAQ:SRDX) ("Surmodics" or the "Company"), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States District Court for the Northern District of Illinois (the "District Court") has denied a request by the U.S. Federal Trade Commission (the "FTC") and certain state regulators to issue a preliminary injunction that would have prevented the Company and GTCR LLC ("GTCR") from consummating the proposed acquisition of the Company by an affiliate of GTCR (the "Merger"). Consummation of the Merger remains subject to a Temporary Restraining Order under which the parties to the Merger agree not to

    11/10/25 7:00:00 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations

    Analysis of the all-comers PROWL Registry demonstrated high procedural success and safety in a cohort reflecting the real-world complexity of patients with symptomatic limb ischemia, over 40% of whom had symptoms lasting more than two weeks before intervention with the Pounce™ Platform. Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that results from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia from its PROWL registry study were presented on November 3rd at an industry-sponsored session at the 23rd Annual VIVA Conference in Las Vegas, NV. PROWL natio

    11/4/25 6:15:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Surmodics downgraded by Barrington Research

    Barrington Research downgraded Surmodics from Mkt Perform to Underperform

    11/14/25 11:19:52 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics upgraded by Lake Street with a new price target

    Lake Street upgraded Surmodics from Hold to Buy and set a new price target of $43.00

    3/7/25 8:21:43 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics upgraded by Needham with a new price target

    Needham upgraded Surmodics from Hold to Buy and set a new price target of $36.00

    6/13/23 7:48:05 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Medical Device Coatings Olson Charles W returned 52,278 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - SURMODICS INC (0000924717) (Issuer)

    11/19/25 6:18:20 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    VP Finance, Corp. Controller Manders John D. returned 8,155 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - SURMODICS INC (0000924717) (Issuer)

    11/19/25 6:16:53 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Sr. VP of Legal, GC and Sec. Weber Gordon S. returned 21,040 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - SURMODICS INC (0000924717) (Issuer)

    11/19/25 6:15:41 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Leadership Updates

    Live Leadership Updates

    View All

    KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Andrew D. C. LaFrence as its Chief Financial Officer, effective July 10, 2023. Andy LaFrence joins KORU Medical bringing over 39 years of finance and accounting experience, including a track record of successfully executing and influencing growth-oriented business and M&A strategies, scaling businesses, developing and managing a global team of finance and accounting

    6/27/23 7:05:00 AM ET
    $KRMD
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Financials

    Live finance-specific insights

    View All

    Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025. Third Quarter Fiscal 2025 Financial Summary Total Revenue of $29.6 million, a decrease of 3% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $29.6 million, an increase of 1% year-over-year GAAP loss of $(5.3) million, compared to $(7.6) million in the prior-year period Adjusted EBITDA(2) of $3.4 million, compared to $1.6 million in the pr

    8/8/25 7:00:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics to Report Third Quarter of Fiscal 2025 Financial Results on August 8

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that third quarter of fiscal year 2025 financial results will be released before the market opens on Friday, August 8. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the third quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also

    8/6/25 4:05:00 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil

    4/30/25 7:00:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

    SC 13G/A - SURMODICS INC (0000924717) (Subject)

    11/14/24 3:36:00 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

    SC 13G/A - SURMODICS INC (0000924717) (Subject)

    11/6/24 1:30:21 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

    SC 13G/A - SURMODICS INC (0000924717) (Subject)

    10/23/24 10:43:41 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care